Inactive Instrument

Genomic Vision

Equities

GV

FR0011799907

Biotechnology & Medical Research

Genomic Vision Reports Sales Results for the First Quarter of 2018

April 27, 2018 at 01:00 am EDT

Genomic Vision reported sales results for the first quarter of 2018. For the quarter, the company reported total revenue from sales of €247,000 against €192,000 a year ago. Total revenue from activity was €627,000 against €537,000 a year ago.

Latest news about Genomic Vision

Genomic Vision Announces Revenue Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Genomic Vision Files for Receivership at French Court	Nov. 06	MT
Genomic Vision Expands Its Replication Combing Assay Service Offering	Nov. 02	CI
Genomic Vision Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-29	CI
Genomic Vision Launches HexaCard	23-07-18	CI
Genomic Vision Société Anonyme announced that it has received ?6 million in funding from Winance Investment, LLC	23-06-22	CI
Global markets live: EssilorLuxottica, AT&T, Tesla, Credit Suisse, Sony...	23-04-21
Genomic Vision Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-20	CI
Genomic Vision Joins France Biolead to Advance Innovation and Production of Biopharmaceuticals in France	23-04-03	CI
Global markets live: Blackberry, Meta Platforms, Rivian, GM...	23-03-07
Genomic Vision Launches FiberSmart, AI-Powered Software for Automating Genomic Analysis	23-03-07	CI
Genomic Vision Reports Unaudited Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-28	CI
Genomic Vision's DNA Characterization Technology Evaluated Successfully in US	23-02-21	MT
The US National Institute of Standards and Technology Evaluates the Use of Genomic Vision Applications for Genetic Variant Characterization	23-02-21	CI
Global markets live: Airbus, Tesla, Meta, Commerzbank...	23-02-20
Genomic Vision Appoints COO	23-01-24	MT
Genomic Vision Announces Appointment of Frederic Hammel as Chief Operating Officer	23-01-24	CI
AstraZeneca, Fritz Lipmann Institute Validate Genomic Vision Integrated Software	23-01-05	MT
Genomic Vision Announces Successful Beta Testing of FiberSmart	23-01-05	CI
Genomic Vision and Centre National de la Recherche Scientifique Launch Core Oncology Program with the Cancer Research Center of Marseille to Develop Companion Tests Based on TeloSizer	22-11-29	CI
Genomic Vision Partners With Cambridge Consultants For Genome Modification Technology Platform	22-11-07	MT
Genomic Vision and Cambridge Consultants Announce the Development of an Innovative Technology Platform for In-Depth Genomic Analysis	22-11-07	CI
Genomic Vision Société Anonyme Announces Revenue Results for the Third Quarter and Nine Months of 2022	22-10-27	CI
Genomic Vision Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-29	CI
Genomic Vision Société Anonyme Reports Unaudited Sales Results for the First Half Ended June 30, 2022	22-07-22	CI

Chart Genomic Vision

Duration

Period

More charts

Company Profile

Genomic Vision specializes in developing genetic diseases diagnosis tests and cancer genomic analysis. The group uses molecular combing technology which allows direct visualization of DNA individual molecules in order to detect the quantitative and qualitative changes of the genome and determine their role in targeted pathology. The activity is organized around 3 sources of income: - sales of equipment and consumables: to academic laboratory centers using the molecular combing technology for research purposes; - license and royalties income: income from collaboration with Quest Diagnostics; - sales of software, testing kits and related consumables.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	-1.78%	41.36B
LONZA GROUP AG	+47.70%	41.3B
MODERNA, INC.	+4.01%	39.61B
CELLTRION, INC.	-15.14%	25.62B
ICON PUBLIC LIMITED COMPANY	+3.16%	24.09B
ALNYLAM PHARMACEUTICALS, INC.	-24.08%	18.38B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.67%	11.82B
MEDPACE HOLDINGS, INC.	+24.76%	11.85B
UNITED THERAPEUTICS CORPORATION	+7.01%	11.07B

Other Biotechnology & Medical Research